Bellwether Risperdal Gynecomastia Lawsuits Scheduled To Begin In November
Written by Stephen Fields on October 10, 2014
Parents of young boys who have experienced abnormal breast growth after taking the antipsychotic medication Risperdal may soon have something to smile about. A number of lawsuits accusing the manufacturer, Johnson & Johnson, of failing to warn parents about the possible risk have been scheduled for a late-2014, early-2015 trial date. These first cases will serve as bellwether trials. They could pave the way for a Risperdal lawsuit settlement with other claimants.
Male breast growth is known as gynecomastia. Researchers have found that the disorder can have a profound and lasting psychological impact on adolescent boys. Risperdal attorneys are currently reviewing potential claims on behalf of young boys who have experienced gynecomastia after taking Johnson & Johnson’s antipsychotic drug. Parents are understandably angered and seek to hold J&J responsible for their families’ suffering.
The bellwether cases that have been scheduled for trial should provide insight on how juries will treat similar claims in the future. If your family has been burdened with Risperdal breast growth side effects, it’s not too late to file a claim for compensation. Call 1-888-210-9968 for a free case evaluation.
Risperdal Lawsuit Claims Scheduled To Start In Late 2014
Three lawsuits have been chosen as bellwethers. The first case is scheduled to get under way on November 3. The second case is scheduled to start on January 3, 2015. The third case is scheduled to begin sometime in February 2015. All 3 complaints name Johnson & Johnson and its subsidiary Janssen Pharmaceuticals as defendants.
These 3 cases are but a small sample of the growing number of lawsuits pending against the manufacturer in the Philadelphia Court of Common Pleas. The litigation includes more than 800 claims filed by families with loved ones who have been harmed by Risperdal.
What Is A Bellwether Trial?
Bellwether trials are used in situations where a large number of people have suffered a similar set of injuries stemming from similar circumstances. In the case of Risperdal, young boys that used the medication unexpectedly grew breasts. The lawsuits filed on their behalf make the same set of allegations.
The courts try to expedite the litigation by choosing several cases deemed to be representative of the larger group. These are known as bellwether cases. Evidence and testimony relevant to the plaintiffs’ claims are presented to juries. The goal is to gain insight regarding the types of verdicts juries are likely to deliver for the other lawsuits in the group.
If jurors deliver verdicts in favor of the plaintiffs, Johnson & Johnson may decide it is better served negotiating settlements with the remaining plaintiffs. The outcomes of the bellwether trials may also inform J&J about a suitable dollar amount to offer claimants.
Allegations Expected To Surface During The Risperdal Litigation
The bellwether trials are expected to address a number of common issues with respect to the link between Risperdal and gynecomastia. For example, the claimants accuse J&J of negligence. The company failed to warn consumers about the possibility that its drug might stimulate breast growth in adolescent boys.
The manufacturer is also facing claims that it deceptively promoted Risperdal as a safe and effective treatment for young boys coping with mental disorders. According to the plaintiffs, J&J purposefully withheld test results demonstrating that use of Risperdal was accompanied by an increased risk of gynecomastia. The company was in a position to know about the potential risk. Deliberately refusing to disclose it indicates fraud.
The plaintiffs note that Johnson & Johnson has been marketing the drug since 1993. Twenty years is sufficient time to uncover serious side effects associated with its use. And yet, the manufacturer did little over the years to warn the public that Risperdal might trigger abnormal breast development in young boys.
Filing A Risperdal Gynecomastia Lawsuit Before The Deadline
Risperdal has been a boon to Johnson & Johnson’s bottom line. It generated more than $24 billion for the pharmaceutical giant between 2003 and 2010. In 2007 alone, sales of the drug exceeded $4.5 billion.
But the revenues were produced while apparently misleading the public about the drug’s potential side effects. Many families are now paying a steep price for trusting the manufacturer.
If someone in your family is suffering from the effects of gynecomastia after using Risperdal, now is the time to learn about your legal options. Call 1-888-210-9968 to speak with our Risperdal settlement lawyers.
There is no cost for the consultation nor any obligation to file a lawsuit. The decision to do so is yours. If you decide to pursue a claim, there are no legal fees unless we obtain compensation for you.
There is limited time to file a claim. Act today before the filing deadline passes. Contact our offices at your earliest convenience to demand the compensation you and your family deserve.